215 related articles for article (PubMed ID: 28282718)
1. The Potential of Circulating Tumor Cells in Personalized Management of Breast Cancer: A Systematic Review.
Khatami F; Aghayan HR; Sanaei M; Heshmat R; Tavangar SM; Larijani B
Acta Med Iran; 2017 Mar; 55(3):175-193. PubMed ID: 28282718
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells in breast cancer: applications in personalized medicine.
Lee JS; Magbanua MJM; Park JW
Breast Cancer Res Treat; 2016 Dec; 160(3):411-424. PubMed ID: 27761678
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
4. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cells in Breast Cancer.
Liang DH; Hall C; Lucci A
Recent Results Cancer Res; 2020; 215():127-145. PubMed ID: 31605227
[TBL] [Abstract][Full Text] [Related]
7. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.
Onstenk W; Gratama JW; Foekens JA; Sleijfer S
Cancer Treat Rev; 2013 Nov; 39(7):691-700. PubMed ID: 23683721
[TBL] [Abstract][Full Text] [Related]
8. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
9. Circulating and disseminated tumor cells in ovarian cancer: a systematic review.
Romero-Laorden N; Olmos D; Fehm T; Garcia-Donas J; Diaz-Padilla I
Gynecol Oncol; 2014 Jun; 133(3):632-9. PubMed ID: 24657303
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges.
Lianidou ES; Markou A
Clin Chem; 2011 Sep; 57(9):1242-55. PubMed ID: 21784769
[TBL] [Abstract][Full Text] [Related]
11. Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer.
Cueva Bañuelos JF; Rodríguez López C; Cortegoso Mosquera A; Palacios Ozores P; Curiel García T
Adv Exp Med Biol; 2020; 1220():147-164. PubMed ID: 32304085
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
Bauer ECA; Schochter F; Widschwendter P; DeGregorio A; Andergassen U; Friedl TWP; Fasching PA; Fehm T; Schneeweiss A; Beckmann MW; Pantel K; Janni W; Rack B; Scholz C;
Breast Cancer Res Treat; 2018 Oct; 171(3):571-580. PubMed ID: 29931425
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells in breast cancer--current status and perspectives.
Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T
Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820
[TBL] [Abstract][Full Text] [Related]
14. Effect of circulating tumor cells combined with negative enrichment and CD45-FISH identification in diagnosis, therapy monitoring and prognosis of primary lung cancer.
Chen YY; Xu GB
Med Oncol; 2014 Dec; 31(12):240. PubMed ID: 25361883
[TBL] [Abstract][Full Text] [Related]
15. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
[TBL] [Abstract][Full Text] [Related]
16. The Role of CTCs as Tumor Biomarkers.
Lianidou ES; Markou A; Strati A
Adv Exp Med Biol; 2015; 867():341-67. PubMed ID: 26530376
[TBL] [Abstract][Full Text] [Related]
17. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.
Androulakis N; Agelaki S; Perraki M; Apostolaki S; Bozionelou V; Pallis A; Kalbakis K; Xyrafas A; Mavroudis D; Georgoulias V
Br J Cancer; 2012 Jun; 106(12):1917-25. PubMed ID: 22669159
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of circulating tumor cells lacking cytokeratins in metastatic breast cancer patients.
Zhao L; Li P; Li F; Yang Y; Liu N; Cai L
J Cancer Res Ther; 2013; 9(1):29-37. PubMed ID: 23575071
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
